comparemela.com

Latest Breaking News On - Holli cherevka - Page 1 : comparemela.com

Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights

/PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the.

United statesBritish columbiaMichael martinoHoward levyNic johnsonMike martinoElizabeth varki jobesHolli cherevkaJ kevin buchiTony russoPrnewswire ampio pharmaceuticals incCompany board of directorsMillion expected to fund current operationsExchange commissionAmpio pharmaceuticalsAmpio pharmaceuticals board of directors

Ampio Pharmaceuticals, Inc Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

/PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for.

United statesBritish columbiaHolli cherevkaMike martinoExchange commissionAmpio pharmaceuticalsAmpio pharmaceuticals incChief operatingPer protocolChief executive officerToll freeInvestor relationsBiologics price competitionInnovation actPrivate securities litigation reform actAnnual report

Ampio Pharmaceuticals, Inc Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the adva.

United statesBritish columbiaHolli cherevkaMike martinoExchange commissionAmpio pharmaceuticalsAmpio pharmaceuticals incChief operatingPer protocolChief executive officerToll freeInvestor relationsBiologics price competitionInnovation actPrivate securities litigation reform actAnnual report

Ampio Pharmaceuticals, Inc Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

/PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for.

United statesBritish columbiaHolli cherevkaMike martinoExchange commissionAmpio pharmaceuticalsAmpio pharmaceuticals incChief operatingPer protocolChief executive officerToll freeInvestor relationsBiologics price competitionInnovation actPrivate securities litigation reform actAnnual report

Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave

ENGLEWOOD, CO, November 22, 2021 – Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced that Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediat

United statesRoanoke collegeHolli cherevkaMike macalusoMichael martinoAmpio pharmaceuticalsAmpio pharmaceuticals incInterim chairmanAmpio boardHemaflo therapeuticsAcute kidney injuryCaravan biologixBiologics price competitionInnovation actFood and drug administrationForward looking statement

vimarsana © 2020. All Rights Reserved.